Kailera Therapeutics (Nasdaq: KLRA) sold 44,921,875 shares in its initial public offering, including the underwriters' full option. A restated charter set up a classified board and exclusive forum rules.
Kailera Therapeutics, Inc. filed a Form S-1 on March 27, 2026. The cover leaves the share count and price range blank.
Questions about Kailera Therapeutics
When did Kailera Therapeutics go public?
Our latest story on this, dated Apr 20, 2026: "Kailera Therapeutics completes IPO with $718.8 million in gross proceeds at $16.00 a share". The story links the filing or release it is based on. Read the story.
Has Kailera Therapeutics raised money recently?
Our latest story on this, dated Apr 20, 2026: "Kailera Therapeutics completes IPO with $718.8 million in gross proceeds at $16.00 a share". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Kailera Therapeutics?
Kailera Therapeutics, Inc. trades under the ticker KLRA on NASDAQ.
Where is Kailera Therapeutics listed?
Kailera Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Kailera Therapeutics?
The SEC Central Index Key (CIK) for Kailera Therapeutics, Inc. is 2096997. Its filings are on SEC EDGAR.
How many shares does Kailera Therapeutics have outstanding?
129,643,676 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Kailera Therapeutics listed under?
Our directory records Kailera Therapeutics, Inc. under United States.
What does Kailera Therapeutics do?
Our directory classifies Kailera Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Kailera Therapeutics?
The ISIN recorded for Kailera Therapeutics, Inc. is US4829311020.
Does aibio.space cover Kailera Therapeutics?
aibio.space lists Kailera Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Kailera Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Kailera Therapeutics (KLRA) stock news?
Our latest story on Kailera Therapeutics, dated Apr 20, 2026: "Kailera Therapeutics completes IPO with $718.8 million in gross proceeds at $16.00 a share". Kailera Therapeutics (Nasdaq: KLRA) sold 44,921,875 shares in its initial public offering, including the underwriters' full option. A restated charter set up a classified board and exclusive forum rules. Source.
Is Kailera Therapeutics a smaller reporting company?
SEC records list Kailera Therapeutics, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.
Where is Kailera Therapeutics headquartered?
SEC records list its business address as 180 THIRD AVENUE, WALTHAM, MA, 02451.
When does Kailera Therapeutics's fiscal year end?
Kailera Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records.
Investor discussion: Kailera Therapeutics
Members talk about Kailera Therapeutics (KLRA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Kailera Therapeutics, newest first. Each line links the filing it comes from.
Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:KLRA on TradingView.
SEC filings and registration
SEC name
Kailera Therapeutics, Inc.
CIK
2096997
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
KLRA (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
180 THIRD AVENUE, WALTHAM, MA, 02451
Phone
508-440-9475
Shares outstanding
129,643,676 as of 2026-08-06 (10-Q filed 2026-08-12)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Kailera Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KLRA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio